Pharmacia on Vioxx vs. Celebrex
"In the last couple of months, we have seen a sharp deceleration in the share growth of Vioxx," Pharmacia Global Business Management President Carrie Cox maintained July 25. "Our goal is for Celebrex [celecoxib] to keep a firm hold on the number one position in the market." New prescriptions grew by 9% from the first quarter to the second, Cox reported. The product has topped $1 bil. in U.S. sales so far in 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth